Lyell Immunopharma, Inc. · NASDAQ:LYEL
James B. Tananbaum's stake in Lyell Immunopharma, Inc. fell to 2.70% (Schedule 13G/A)
Event Jun 30, 2026 · Filed Aug 14, 2026
James B. Tananbaum's stake in Lyell Immunopharma, Inc. fell to 2.70%, 653,328 shares, as a passive investor on Jun 30, 2026. Filed Aug 14, 2026 (Schedule 13G/A).
- Stake
- 2.70%
- Shares
- 653,328
- Intent
- Passive
- What changed
- Fell below 5%
- Filed together
- 7 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Foresite Capital Fund IV, L.P. | 0% | 0 |
| Foresite Capital Management IV, LLC | 0% | 0 |
| Foresite Capital Fund V, L.P. | 1.90% | 476,386 |
| Foresite Capital Management V, LLC | 1.90% | 476,386 |
| Foresite Capital Opportunity Fund V, L.P. | 0.70% | 176,942 |
| Foresite Capital Opportunity Management V, LLC | 0.70% | 176,942 |
| James B. Tananbaum | 2.70% | 653,328 |
Source
Related
- Lyell Immunopharma, Inc.
- James B. Tananbaum
- Lyell Immunopharma, Inc. shareholders
- Schedule 13G/A · James B. Tananbaum · Nov 14, 2025
- Form 4 · Aguirre Jarrad Mattieu · Oct 13, 2026
- Form 4 · Shook David · Sep 10, 2026
- Form 4 · Seely Lynn · Aug 25, 2026
- Form 4 · Hill Stephen J. · Aug 25, 2026
- Form 4 · Lee Gary K. · Aug 25, 2026